Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.2.1. Product Segment
1.2.2. End-use Segment
1.3. Research Assumptions
1.4. Information Procurement
1.4.1. Primary Research
1.5. Information or Data Analysis
1.6. Market Formulation & Validation
1.7. Market Model
1.8. Global Market: CAGR Calculation
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
1.9.3. Objective 3
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Trends And Outlook
3.3. Market Dynamics
3.3.1. Increasing Demand For Analytical Instruments
3.3.2. Growing Prevalence Of Target Diseases And Rising Geriatric Population
3.3.3. Technological Advancements In Research-Use Instruments
3.4. Market Restraint Analysis
3.4.1. Higher Cost Of Devices
3.4.2. Shortage Of Skilled Professionals
3.5. Business Environment Analysis
3.5.1. PESTEL Analysis
3.5.2. Porter’s Five Forces Analysis
3.5.3. COVID-19 Impact Analysis
Chapter 4. Product Business Analysis
4.1. Biotechnology Instruments Market: Product Movement Analysis
4.2. Analytical Instruments
4.2.1. Analytical Instruments Market, 2018 – 2030 (USD Million)
4.2.2. Polymerase Chain Reaction
4.2.2.1. Polymerase Chain Reaction, 2018 – 2030 (USD Million)
4.2.3. Spectroscopy
4.2.3.1. Spectroscopy, 2018 – 2030 (USD Million)
4.2.4. Microscopy
4.2.4.1. Microscopy, 2018 – 2030 (USD Million)
4.2.5. Chromatography
4.2.5.1. Chromatography, 2018 – 2030 (USD Million)
4.2.6. Flow Cytometry
4.2.6.1. Flow Cytometry, 2018 – 2030 (USD Million)
4.2.7. Sequencing
4.2.7.1. Sequencing, 2018 – 2030 (USD Million)
4.2.8. Microarray
4.2.8.1. Microarray, 2018 – 2030 (USD Million)
4.2.9. Others
4.2.9.1. Others, 2018 – 2030 (USD Million)
4.3. Cell Culture Instruments
4.3.1. Cell Culture Instruments Market, 2018 – 2030 (USD Million)
4.3.2. Culture Systems
4.3.2.1. Culture Systems Market, 2018 – 2030 (USD Million)
4.3.3. Incubators
4.3.3.1. Incubators Market, 2018 – 2030 (USD Million)
4.3.4. Cryostorage Equipment
4.3.4.1. Cryostorage Equipment Market, 2018 – 2030 (USD Million)
4.3.5. Biosafety Equipment
4.3.5.1. Biosafety Equipment Market, 2018 – 2030 (USD Million)
4.3.6. Pipetting Instruments
4.3.6.1. Pipetting Instruments Market, 2018 – 2030 (USD Million)
4.4. Cell Separation Instruments
4.4.1. Cell Separation Instruments Market, 2018 – 2030 (USD Million)
4.4.2. Centrifuge
4.4.2.1. Centrifuge Market, 2018 – 2030 (USD Million)
4.4.3. Filtration Systems
4.4.3.1. Filtration Systems Market, 2018 – 2030 (USD Million)
4.4.4. Magnetic-activated Cell Separator Systems
4.4.4.1. Magnetic-activated Cell Separator Systems Market, 2018 – 2030 (USD Million)
4.5. Immunoassay Instruments
4.5.1. Immunoassay Instruments Market, 2018 – 2030 (USD Million)
4.6. Clinical Chemistry Analyzers
4.6.1. Clinical Chemistry Analyzers Market, 2018 – 2030 (USD Million)
4.7. Others
4.7.1. Others Market, 2018 – 2030 (USD Million)
Chapter 5. End-use Business Analysis
5.1. Biotechnology Instruments Market: End-use Movement Analysis
5.2. Pharmaceutical & Biotechnology Companies
5.2.1. Pharmaceutical & Biotechnology Companies Market, 2018 – 2030 (USD Million)
5.3. Hospitals & Diagnostic Laboratories
5.3.1. Hospitals & Diagnostics Laboratories Market, 2018 – 2030 (USD Million)
5.4. Academic & Research Institutes
5.4.1. Academic & Research Institutes Market, 2018 – 2030 (USD Million)
5.5. Others
5.5.1. Others Market, 2018 – 2030 (USD Million)
Chapter 6. Regional Business Analysis
6.1. Regional Market Snapshot
6.2. North America
6.2.1. North America Biotechnology Instruments Market, 2018 – 2030 (USD Million)
6.2.2. U.S.
6.2.2.1. U.S. Biotechnology Instruments Market, 2018 – 2030 (USD Million)
6.2.2.2. Key Country Dynamics
6.2.2.3. Competitive Scenario
6.2.2.4. Target Disease Prevalence
6.2.2.5. Regulatory Framework
6.2.3. Canada
6.2.3.1. Canada Biotechnology Instruments Market, 2018 – 2030 (USD Million)
6.2.3.2. Key Country Dynamics
6.2.3.3. Competitive Scenario
6.2.3.4. Target Disease Prevalence
6.2.3.5. Regulatory Framework
6.3. Europe
6.3.1. Europe Biotechnology Instruments Market, 2018 – 2030 (USD Million)
6.3.2. UK
6.3.2.1. UK Biotechnology Instruments Market, 2018 – 2030 (USD Million)
6.3.2.2. Key Country Dynamics
6.3.2.3. Competitive Scenario
6.3.2.4. Target Disease Prevalence
6.3.2.5. Regulatory Framework
6.3.3. Germany
6.3.3.1. Germany Biotechnology Instruments Market, 2018 – 2030 (USD Million)
6.3.3.2. Key Country Dynamics
6.3.3.3. Competitive Scenario
6.3.3.4. Target Disease Prevalence
6.3.3.5. Regulatory Framework
6.3.4. Spain
6.3.4.1. Spain Biotechnology Instruments Market, 2018 – 2030 (USD Million)
6.3.4.2. Key Country Dynamics
6.3.4.3. Competitive Scenario
6.3.4.4. Target Disease Prevalence
6.3.4.5. Regulatory Framework
6.3.5. France
6.3.5.1. France Biotechnology Instruments Market, 2018 – 2030 (USD Million)
6.3.5.2. Key Country Dynamics
6.3.5.3. Competitive Scenario
6.3.5.4. Target Disease Prevalence
6.3.5.5. Regulatory Framework
6.3.6. Italy
6.3.6.1. Italy Biotechnology Instruments Market, 2018 – 2030 (USD Million)
6.3.6.2. Key Country Dynamics
6.3.6.3. Competitive Scenario
6.3.6.4. Target Disease Prevalence
6.3.6.5. Regulatory Framework
6.3.7. Denmark
6.3.7.1. Denmark Biotechnology Instruments Market, 2018 – 2030 (USD Million)
6.3.7.2. Key Country Dynamics
6.3.7.3. Competitive Scenario
6.3.7.4. Target Disease Prevalence
6.3.7.5. Regulatory Framework
6.3.8. Sweden
6.3.8.1. Sweden Biotechnology Instruments Market, 2018 – 2030 (USD Million)
6.3.8.2. Key Country Dynamics
6.3.8.3. Competitive Scenario
6.3.8.4. Target Disease Prevalence
6.3.8.5. Regulatory Framework
6.3.9. Norway
6.3.9.1. Norway Biotechnology Instruments Market, 2018 – 2030 (USD Million)
6.3.9.2. Key Country Dynamics
6.3.9.3. Competitive Scenario
6.3.9.4. Target Disease Prevalence
6.3.9.5. Regulatory Framework
6.4. Asia Pacific
6.4.1. Asia-Pacific Biotechnology Instruments Market, 2018 – 2030 (USD Million)
6.4.2. Japan
6.4.2.1. Japan Biotechnology Instruments Market, 2018 – 2030 (USD Million)
6.4.2.2. Key Country Dynamics
6.4.2.3. Competitive Scenario
6.4.2.4. Target Disease Prevalence
6.4.2.5. Regulatory Framework
6.4.3. China
6.4.3.1. China Biotechnology Instruments Market, 2018 – 2030 (USD Million)
6.4.3.2. Key Country Dynamics
6.4.3.3. Competitive Scenario
6.4.3.4. Target Disease Prevalence
6.4.3.5. Regulatory Framework
6.4.4. India
6.4.4.1. India Biotechnology Instruments Market, 2018 – 2030 (USD Million)
6.4.4.2. Key Country Dynamics
6.4.4.3. Competitive Scenario
6.4.4.4. Target Disease Prevalence
6.4.4.5. Regulatory Framework
6.4.5. South Korea
6.4.5.1. South Korea Biotechnology Instruments Market, 2018 – 2030 (USD Million)
6.4.5.2. Key Country Dynamics
6.4.5.3. Competitive Scenario
6.4.5.4. Target Disease Prevalence
6.4.5.5. Regulatory Framework
6.4.6. Thailand
6.4.6.1. Thailand Biotechnology Instruments Market, 2018 – 2030 (USD Million)
6.4.6.2. Key Country Dynamics
6.4.6.3. Competitive Scenario
6.4.6.4. Target Disease Prevalence
6.4.6.5. Regulatory Framework
6.4.7. Australia
6.4.7.1. Australia Biotechnology Instruments Market, 2018 – 2030 (USD Million)
6.4.7.2. Key Country Dynamics
6.4.7.3. Competitive Scenario
6.4.7.4. Target Disease Prevalence
6.4.7.5. Regulatory Framework
6.5. Latin America
6.5.1. Latin America Biotechnology Instruments Market, 2018 – 2030 (USD Million)
6.5.2. Brazil
6.5.2.1. Brazil Biotechnology Instruments Market, 2018 – 2030 (USD Million)
6.5.2.2. Key Country Dynamics
6.5.2.3. Competitive Scenario
6.5.2.4. Target Disease Prevalence
6.5.2.5. Regulatory Framework
6.5.3. Mexico
6.5.3.1. Mexico Biotechnology Instruments Market, 2018 – 2030 (USD Million)
6.5.3.2. Key Country Dynamics
6.5.3.3. Competitive Scenario
6.5.3.4. Target Disease Prevalence
6.5.3.5. Regulatory Framework
6.5.4. Argentina
6.5.4.1. Argentina Biotechnology Instruments Market, 2018 – 2030 (USD Million)
6.5.4.2. Key Country Dynamics
6.5.4.3. Competitive Scenario
6.5.4.4. Target Disease Prevalence
6.5.4.5. Regulatory Framework
6.6. MEA
6.6.1. MEA Biotechnology Instruments Market, 2018 – 2030 (USD Million)
6.6.2. South Africa
6.6.2.1. South Africa Biotechnology Instruments Market, 2018 – 2030 (USD Million)
6.6.2.2. Key Country Dynamics
6.6.2.3. Competitive Scenario
6.6.2.4. Target Disease Prevalence
6.6.2.5. Regulatory Framework
6.6.3. Saudi Arabia
6.6.3.1. Saudi Arabia Biotechnology Instruments Market, 2018 – 2030 (USD Million)
6.6.3.2. Key Country Dynamics
6.6.3.3. Competitive Scenario
6.6.3.4. Target Disease Prevalence
6.6.3.5. Regulatory Framework
6.6.4. UAE
6.6.4.1. UAE Biotechnology Instruments Market, 2018 – 2030 (USD Million)
6.6.4.2. Key Country Dynamics
6.6.4.3. Competitive Scenario
6.6.4.4. Target Disease Prevalence
6.6.4.5. Regulatory Framework
6.6.5. Kuwait
6.6.5.1. Kuwait Biotechnology Instruments Market, 2018 – 2030 (USD Million)
6.6.5.2. Key Country Dynamics
6.6.5.3. Competitive Scenario
6.6.5.4. Target Disease Prevalence
6.6.5.5. Regulatory Framework
Chapter 7. Competitive Landscape
7.1. Company Categorization
7.2. Strategy Mapping
7.3. Company Market Share Analysis, 2022
7.4. Company Profiles/Listing
7.4.1. Thermo Fisher Scientific, Inc.
7.4.1.1. Company Overview
7.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.1.3. Product Benchmarking
7.4.1.4. Strategic Initiatives
7.4.2. Waters Corp.
7.4.2.1. Company Overview
7.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.2.3. Product Benchmarking
7.4.2.4. Strategic Initiatives
7.4.3. Shimadzu Corp.
7.4.3.1. Company Overview
7.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.3.3. Product Benchmarking
7.4.3.4. Strategic Initiatives
7.4.4. Danaher
7.4.4.1. Company Overview
7.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.4.3. Product Benchmarking
7.4.4.4. Strategic Initiatives
7.4.5. Agilent Technologies, Inc.
7.4.5.1. Company Overview
7.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.5.3. Product Benchmarking
7.4.5.4. Strategic Initiatives
7.4.6. Bruker Corp.
7.4.6.1. Company Overview
7.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.6.3. Product Benchmarking
7.4.6.4. Strategic Initiatives
7.4.7. PerkinElmer, Inc.
7.4.7.1. Company Overview
7.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.7.3. Product Benchmarking
7.4.7.4. Strategic Initiatives
7.4.8. Mettler Toledo
7.4.8.1. Company Overview
7.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.8.3. Product Benchmarking
7.4.8.4. Strategic Initiatives
7.4.9. Zeiss Group
7.4.9.1. Company Overview
7.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.9.3. Product Benchmarking
7.4.9.4. Strategic Initiatives
7.4.10. Bio-Rad Laboratories, Inc.
7.4.10.1. Company Overview
7.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.10.3. Product Benchmarking
7.4.10.4. Strategic Initiatives
7.4.11. Illumina, Inc.
7.4.11.1. Company Overview
7.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.11.3. Product Benchmarking
7.4.11.4. Strategic Initiatives
7.4.12. Eppendorf SE
7.4.12.1. Company Overview
7.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.12.3. Product Benchmarking
7.4.12.4. Strategic Initiatives
7.4.13. F. Hoffmann-La Roche AG
7.4.13.1. Company Overview
7.4.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.13.3. Product Benchmarking
7.4.13.4. Strategic Initiatives
7.4.14. Sartorius AG
7.4.14.1. Company Overview
7.4.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.14.3. Product Benchmarking
7.4.14.4. Strategic Initiatives
7.4.15. Avantor, Inc.
7.4.15.1. Company Overview
7.4.15.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.15.3. Product Benchmarking
7.4.15.4. Strategic Initiatives
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer